Financial Performance - The unaudited revenue for the Group for the three months ended March 31, 2023, was approximately S$309,000, a decrease of approximately S$450,000 or 59.29% compared to S$759,000 for the same period in 2022[7]. - The unaudited loss for the Group was approximately S$1,827,000 for the three months ended March 31, 2023, representing a decrease in losses of approximately S$250,000 or 12.04% compared to S$2,077,000 for the same period in 2022[7]. - Loss per share for the Company was approximately 0.15 Singapore cents for the three months ended March 31, 2023, compared to 0.22 Singapore cents for the same period in 2022[7]. - Total comprehensive loss for the period was S$1,535,000 for the three months ended March 31, 2023, compared to S$2,055,000 for the same period in 2022[8]. - The company reported a loss for the period of S$1,713,000 for the first quarter of 2023, compared to a loss of S$2,529,000 for the same period in 2022, representing a reduction in losses of approximately 32%[10]. - The Group reported a foreign currency translation loss of S$292,000 for the three months ended March 31, 2023, compared to a gain of S$22,000 for the same period in 2022[8]. - The company recorded a loss of approximately S$1,827,000 for the three months ended March 31, 2023, a decrease of approximately S$250,000 or 12.04% compared to a loss of approximately S$2,077,000 for the same period in 2022[88]. Revenue Breakdown - Revenue from dental services amounted to S$264,000, while trading sales contributed S$45,000, indicating a significant shift in revenue sources[31]. - Revenue from external customers in Hong Kong was S$45,000, down from S$759,000 in the previous year, while revenue from China was S$264,000, which was not reported in the prior year[33]. - Revenue from Dental Services amounted to S$264,000, accounting for approximately 85% of total revenue for the three months ended March 31, 2023[60][61]. - Trading Sales contributed approximately S$45,000, representing a significant decrease of approximately S$714,000 compared to S$759,000 for the three months ended March 31, 2022[63][68]. - Total revenue for the three months ended March 31, 2023, was S$309,000, a decrease of 59.3% compared to S$759,000 for the same period in 2022[28]. Operating Income and Expenses - Other operating income increased to S$572,000 for the three months ended March 31, 2023, compared to S$73,000 for the same period in 2022[8]. - Other operating income for the three months ended March 31, 2023, was approximately S$572,000, which represented an increase of S$499,000 compared to S$73,000 for the same period in 2022[64][69]. - Employee benefits expense was S$797,000 for the three months ended March 31, 2023, compared to S$765,000 for the same period in 2022[8]. - Other operating expenses rose by approximately S$296,000 or 30.42%, from approximately S$973,000 for the three months ended March 31, 2022, to approximately S$1,269,000 for the same period in 2023[85]. - Consumables and medical supplies used amounted to approximately S$163,000 for the three months ended March 31, 2023, down from S$638,000 in the same period in 2022[65][70]. Corporate Governance and Compliance - The Company has adopted a code of conduct for securities transactions by directors, which was complied with throughout the three months ended March 31, 2023[119]. - The Audit Committee consists of three independent non-executive Directors, ensuring oversight of financial reporting and internal controls[133]. - The company complied with all applicable code provisions of the Corporate Governance Code during the three months ended March 31, 2023[107]. - The independent non-executive Directors confirmed compliance with the non-competition undertakings for the three months ended March 31, 2023[125]. - The Board is committed to high standards of corporate governance to manage business risks and enhance transparency[106]. Future Outlook and Strategic Focus - The Company will shift its core business operations to dental implant services, supported by a two-year business development plan established in 2022[51][55]. - The Company identifies a significant market potential for dental implant services in mainland China, driven by a large population and aging demographics[52][55]. - The Group aims to concentrate resources on the continuous development of dental services while maintaining a prudent investment strategy[53][55]. - Future outlook remains cautious due to ongoing market challenges and the need for strategic adjustments in operations[29]. Shareholder Information - As of March 31, 2023, Dr. Loh Teck Hiong holds 210,024,000 shares, representing approximately 15.77% of the company's total shareholding[97]. - Mr. Lee Chung Shun was allotted 6,000,000 shares on January 12, 2023, following the full exercise of share options granted under the Share Option Scheme[97]. - Brisk Success, a beneficial owner, holds 210,024,000 shares, equivalent to 15.77% of the total shareholding[104]. - HK MZ Health Investment Management Group Limited holds 132,968,000 shares, accounting for 9.98% of the total shareholding[104]. - The total number of share options granted as of March 31, 2023, is 30,000,000, with 18,000,000 exercised and 12,000,000 lapsed[115].

Financial Performance - For the year ended December 31, 2023, the group's revenue was approximately SGD 3,180,000, a decrease of about SGD 1,061,000 or 25% compared to the year ended December 31, 2022[6]. - The group recorded a loss from continuing operations of approximately SGD 6,853,000, a reduction of about SGD 6,274,000 or 47.8% compared to the loss of SGD 13,127,000 for the year ended December 31, 2022[6]. - Basic loss per share from continuing operations for the year ended December 31, 2023, was 0.51 Singapore cents, compared to 1.01 Singapore cents for the year ended December 31, 2022[6]. - Total comprehensive loss for the year was SGD 6,559,000, down from SGD 18,639,000 in the previous year[8]. - The group reported a net loss of SGD 6,749,000 attributable to owners of the company for the year ended December 31, 2023[22]. - The company reported a pre-tax loss of SGD 6,749,000 for 2023, a decrease from a loss of SGD 18,649,000 in 2022, representing a 63.8% improvement[49]. - Basic and diluted loss per share for 2023 was SGD 0.51, compared to SGD 1.44 in 2022, indicating a 64.6% reduction in loss per share[49]. - The company recorded a net foreign exchange loss of SGD 376,000 in 2023, compared to a gain of SGD 102,000 in 2022[43]. - Total other income and losses for 2023 amounted to SGD 338,000, significantly lower than SGD 4,529,000 in 2022, reflecting a decrease of 92.6%[43]. - The company reported a total loss of approximately SGD 12.5 million as of December 31, 2023, compared to a loss of about SGD 6.3 million in 2022[74]. Revenue Breakdown - Total revenue for 2023 was SGD 3,180,000, a decrease of 25% from SGD 4,241,000 in 2022[31]. - Dental services revenue increased significantly to SGD 1,632,000 in 2023 from SGD 216,000 in 2022, representing a growth of 655%[31]. - Revenue from the sale of dental implants and oral health-related products rose to SGD 246,000 in 2023, up from SGD 91,000 in 2022, marking a 170% increase[31]. - Trade sales revenue decreased to SGD 1,141,000 in 2023 from SGD 3,326,000 in 2022, a decline of 66%[31]. - Revenue from external customers in China increased to SGD 2,039,000 in 2023 from SGD 915,000 in 2022, a growth of 123%[38]. - The group did not recognize any revenue from discontinued operations in 2023, compared to SGD 9,034,000 in 2022[31]. - Revenue from health products, nutritional supplements, and related medical beauty products was approximately SGD 1,141,000, a decrease of about SGD 2,185,000 or 65.7% compared to SGD 3,326,000 for the year ended December 31, 2022[59]. - The dental business generated sales of SGD 2,039,000, an increase of approximately SGD 1,124,000 or 122.8% compared to SGD 915,000 for the year ended December 31, 2022[61]. Assets and Liabilities - Non-current assets decreased from SGD 4,024,000 in 2022 to SGD 1,008,000 in 2023, primarily due to a significant reduction in right-of-use assets[10]. - Current assets decreased from SGD 8,372,000 in 2022 to SGD 3,140,000 in 2023, with trade and other receivables dropping from SGD 5,201,000 to SGD 1,841,000[10]. - Current liabilities increased slightly from SGD 15,137,000 in 2022 to SGD 15,242,000 in 2023, leading to a net current liability position of SGD 12,102,000[10]. - The total equity attributable to owners of the company decreased from SGD 6,288,000 in 2022 to SGD 12,407,000 in 2023, reflecting the overall loss incurred[11]. - As of December 31, 2023, the group's current liabilities exceeded its current assets by SGD 12,102,000[22]. - The financial guarantee provided to the Singapore liquidated subsidiaries amounted to approximately SGD 4,076,000, recognized as current liabilities[22]. - The company’s total liabilities included SGD 8,388,000 in other payables as of December 31, 2023, up from SGD 7,562,000 in 2022, an increase of 10.9%[53]. - The company's net liabilities increased to approximately SGD 12,519,000 as of December 31, 2023, compared to SGD 6,296,000 as of December 31, 2022[72]. - The company's net current liabilities amounted to approximately SGD 12.1 million as of December 31, 2023, compared to about SGD 6.8 million in 2022[74]. Cash Flow and Liquidity - The company’s cash and cash equivalents were approximately SGD 306,000 as of December 31, 2023, indicating insufficient liquidity to meet immediate repayment obligations[22]. - The company has cash and cash equivalents of SGD 306,000, indicating insufficient liquidity to settle financial guarantee liabilities[98]. - The company plans to implement measures to improve liquidity and financial condition over the next twelve months[99]. - The company is exploring financing options, including attracting new investors and issuing debt securities[100]. Operational Changes and Future Plans - The group has taken measures to alleviate cash flow pressure and improve its financial position, including engaging with financial institutions providing bank financing[22]. - The company is actively seeking alternative financing solutions, including plans to introduce new investors or issue debt and equity securities[27]. - The group has terminated the consolidation of the Singapore liquidated subsidiaries, resulting in the exclusion of their financial performance from the consolidated financial statements[18]. - The board has implemented a new business plan and strategy to revitalize the healthcare services segment, integrating it with dental and trading businesses[91]. - Future focus will be on promoting and developing healthcare services through Wong Yan Medical in Hong Kong[92]. - The independent auditor has not issued an opinion on the consolidated financial statements due to significant uncertainties regarding the company's ability to continue as a going concern[96]. Corporate Governance - The company has adopted the corporate governance code and has committed to improving its governance practices[85]. - The company has signed a shareholders' agreement with Wong Yan Medical Limited, gaining control over its board[91]. Dividends - The company did not recommend the payment of a final dividend for the year ended December 31, 2023[6]. - The company did not declare a final dividend for the year ending December 31, 2023, consistent with the previous year[47].

Financial Performance - The unaudited revenue of RMH Holdings Limited for the nine months ended September 30, 2023, was approximately S$2,250,000, representing a decrease of approximately S$169,000 or 7.0% compared to S$2,419,000 for the same period in 2022[11]. - The unaudited loss for the Group was approximately S$3,921,000 for the nine months ended September 30, 2023, a decrease of approximately S$1,579,000 or 28.7% from a loss of S$5,500,000 for the same period in 2022[11]. - Loss per share for the Company was approximately 0.31 Singapore cents for the nine months ended September 30, 2023, compared to 0.47 Singapore cents for the same period in 2022[11]. - The total comprehensive expenses for the period amounted to S$3,790,000, compared to S$5,848,000 for the same period in 2022[12]. - The company reported a loss before taxation of S$3,921,000 for the nine months ended September 30, 2023, compared to a loss of S$5,500,000 in the same period of 2022, indicating an improvement of about 29%[104]. - The total comprehensive loss for the nine months ended September 30, 2022, was S$6,233,000, indicating a worsening financial position compared to the current period[14]. Revenue Breakdown - Dental services generated revenue of S$1,472,000 for the nine months ended September 30, 2023, with trading sales contributing S$778,000[89]. - Revenue from trading sales decreased significantly from S$2,419,000 in 2022 to S$778,000 in 2023, indicating a decline of approximately 68%[89]. - Revenue recognition for healthcare services is primarily at a point in time, with all S$2,250,000 recognized in this manner for the nine months ended September 30, 2023[89]. - The Group's revenue from aesthetic services is generally received upfront and recognized as deferred revenue, reflecting a stable cash flow model[74]. - Revenue from consultation services is typically recognized over a period of less than one day, indicating a quick turnaround in service delivery[75]. - Revenue from prescription and dispensing services is recognized at the point when the patient obtains control of the medication, ensuring timely revenue recognition[81]. Operating Expenses - Employee benefits expense decreased to S$2,011,000 for the nine months ended September 30, 2023, from S$2,396,000 in the same period in 2022[12]. - Other operating expenses decreased to S$2,639,000 for the nine months ended September 30, 2023, from S$2,910,000 for the same period in 2022[12]. - The Group's cost of consumables and medical supplies used was approximately S$1,000,000 for the nine months ended September 30, 2023, down from approximately S$1,099,000 in 2022[126][130]. - Other income increased significantly to S$952,000 in the nine months ended September 30, 2023, from S$48,000 in the same period of 2022[94]. - Finance costs decreased to S$48,000 for the nine months ended September 30, 2023, down from S$86,000 in the same period of 2022, reflecting a reduction of approximately 44%[95]. Corporate Governance - The company complied with all applicable code provisions of the Corporate Governance Code during the nine months ended September 30, 2023[172]. - The board is committed to high standards of corporate governance to manage business risks and enhance transparency[171]. - The Audit Committee consists of three independent non-executive directors, ensuring compliance with GEM Listing Rules[196]. - The company has adopted a code of conduct for directors' securities transactions that meets or exceeds GEM Listing Rules standards[184]. - The company will continue to review and improve its corporate governance practices[171]. Shareholder Information - The company did not recommend the payment of any dividend for the nine months ended September 30, 2023[11]. - The weighted average number of ordinary shares in issue increased to 1,260,536,000 for the nine months ended September 30, 2023, from 1,174,599,000 in the same period of 2022[104]. - The total number of share options as of September 30, 2023, is 30,000,000, with 18,000,000 exercised and 12,000,000 lapsed[180]. - The company has adopted a share option scheme, granting a total of 60,000,000 share options to ten directors and eligible participants at an exercise price of HK$0.109 per share[177]. - The company did not purchase, sell, or redeem any of its listed securities during the nine months ended September 30, 2023[182]. Business Strategy - The Company plans to shift its core business operations to dental implant services, supported by a two-year business development plan established in 2022[114][118]. - The Company identifies a significant market potential for dental implant services in mainland China, driven by a large population and aging demographics[115][115]. - The core business has transitioned from dermatology aesthetic services to dental care and dental implant services due to changes in the business environment[121][122]. - The Group will focus resources on the continuous development of dental services while maintaining a prudent investment strategy[116][116]. - The Group's operational performance will be closely monitored to maximize shareholder value[116][116].

Financial Performance - The unaudited revenue of RMH Holdings Limited for the six months ended 30 June 2023 was approximately S$1,309,000, representing a decrease of approximately S$637,000 or 32.7% compared to S$1,946,000 for the same period in 2022[11]. - The unaudited loss for the Group was approximately S$2,794,000 for the six months ended 30 June 2023, an increase of approximately S$2,154,000 or 43.5% compared to losses of S$4,948,000 for the same period in 2022[11]. - Loss per share was 0.20 Singapore cents for the six months ended 30 June 2023, compared to 0.37 Singapore cents for the same period in 2022[11]. - The Group incurred a loss before tax of S$2,794,000, an improvement from a loss of S$4,154,000 in the prior year, indicating a reduction in losses by approximately 32.8%[35]. - The total loss for the period was S$2,794,000, compared to S$4,948,000 in the previous year, indicating a reduction of 43%[39]. - Total comprehensive income for the period was a loss of S$2,661,000, compared to a loss of S$5,046,000 for the same period in 2022, indicating a 47.3% improvement[46]. - The loss for the period attributable to owners of the Company from continuing operations was S$2,699,000, a decrease of 35% compared to S$4,154,000 in the same period of 2022[39]. - The total comprehensive expense for the period attributable to owners of the Company from continuing operations was S$2,566,000, down from S$4,254,000, reflecting a 40% improvement[39]. Financial Position - The Group had net current liabilities of S$9,389,000 and net liabilities of S$8,612,000 as of 30 June 2023[14]. - The Group's cash and cash equivalent balance was S$77,000 as of 30 June 2023, indicating insufficient funds for immediate settlement of borrowings and financial guarantee liabilities[18]. - The Group's liquidity and financial position are under significant uncertainty, with multiple factors affecting its ability to continue as a going concern[21]. - The Group's financial position raises concerns regarding its ability to continue as a going concern due to significant liabilities and insufficient cash[14]. - The Group's financial statements have not been audited, and a disclaimer of opinion was issued due to the uncertainties surrounding the going concern basis[27]. - As of June 30, 2023, the Group's current liabilities exceeded its current assets by S$9,389,000[58]. - The Group's cash and cash equivalents were approximately S$77,000, indicating insufficient liquidity to settle outstanding balances upon immediate repayment[58]. - The net liabilities increased to S$8,612,000 from S$6,296,000, indicating a 37% increase[43]. - The total deficit of the Group was approximately S$8,612,000, an increase from approximately S$6,296,000 as of December 31, 2022[196]. - The gearing ratio of the Group as of June 30, 2023, was approximately 213.0%, a decrease from 296.9% as of December 31, 2022[197]. Operational Changes - The losses were mainly attributed to other operating expenses and employee benefits expense[11]. - The Group is exploring new business segments to improve operations and generate sufficient operating cash inflow[21]. - The Group will improve operational efficiency by expanding into new segments and reducing operating costs[63]. - The Group's revenue decline was primarily due to significant business restructuring and the inability of its Singapore subsidiaries to pay their debts, leading to liquidation and judicial management proceedings[148]. - The Company has developed a two-year business development plan to enhance its dental services, reflecting a proactive approach to market expansion[152]. Cash Flow and Investments - Cash used in operating activities was S$1,189,000, a significant decrease from S$3,706,000 in the first half of 2022, reflecting a 67.9% improvement[46]. - Cash from investing activities was S$1,134,000, a recovery from cash used of S$2,406,000 in the previous year[49]. - The company issued new shares, raising S$7,469,000, while incurring transaction costs of S$277,000 related to the share placement[49]. - The company acquired plant and equipment amounting to approximately S$397,000 for the six months ended 30 June 2023, a decrease of 36.5% from S$626,000 in the same period of 2022[12][98]. Shareholder Returns - The Board did not recommend the payment of an interim dividend for the six months ended 30 June 2023[11]. - The Board did not recommend any interim dividend for the six months ended June 30, 2023, consistent with the previous period[193]. Compliance and Standards - The Group has adopted all new and revised IFRSs relevant to its operations effective from January 1, 2023, with no material impact on financial statements[69]. - The company adopted new and revised international financial reporting standards effective from January 1, 2023, with no significant impact on the financial statements[74]. - The management anticipates that the adoption of upcoming international financial reporting standards will not have a significant impact on the financial statements during the initial adoption period[74]. Related Party Transactions - The amount due to a related party as of 30 June 2023 was S$2,474,000, slightly down from S$2,493,000 as of 31 December 2022[143]. - Other payables included S$4,768,000 due to Singapore Liquidated Subsidiaries, unchanged from December 31, 2022, with an outstanding balance of S$6,600,000 under negotiation for settlement[121]. Employee and Management Information - The total employee benefits expense for the six months ended June 30, 2023, was S$1,449,000, a decrease from S$1,569,000 in the same period of 2022, primarily due to changes in staffing[175][176]. - The total staff count (excluding directors) decreased from 75 in 2022 to 32 in 2023[178]. - Key management personnel compensation details were disclosed, reflecting the company's commitment to transparency in executive remuneration[141].

Financial Performance - The unaudited revenue for the Group for the three months ended March 31, 2023, was approximately S$309,000, a decrease of approximately S$450,000 or 59.29% compared to S$759,000 for the same period in 2022[10]. - The unaudited loss for the Group was approximately S$1,827,000 for the three months ended March 31, 2023, representing a decrease in losses of approximately S$250,000 or 12.04% compared to a loss of S$2,077,000 for the same period in 2022[10]. - Loss per share for the Company was approximately 0.15 Singapore cents for the three months ended March 31, 2023, compared to 0.22 Singapore cents for the same period in 2022[10]. - Total comprehensive loss for the period was S$1,535,000, compared to S$2,055,000 for the same period in 2022[11]. - The Group's loss before tax was S$1,827,000 for the three months ended March 31, 2023[11]. - The company reported a loss before taxation of S$1,826,000 for the three months ended March 31, 2023, compared to a loss of S$2,077,000 in the same period last year, showing an improvement[34]. - The total comprehensive loss for the same period in 2022 was S$2,507,000, indicating a year-over-year improvement in performance[13]. Revenue Sources - Revenue analysis indicates that the Group's revenue is derived from the provision of medical, dermatological, and aesthetic services and products[15]. - Revenue from dental services was S$264,000, while trading sales contributed S$45,000, indicating a significant shift in revenue sources[34]. - Revenue from Hong Kong was S$45,000, down from S$759,000 in the previous year, while revenue from China was S$264,000, reflecting a new market focus[36]. - Revenue from Dental Services amounted to S$264,000, accounting for approximately 85% of total revenue for the three months ended March 31, 2023[63]. - Total revenue for the three months ended March 31, 2023, was S$309,000, a decrease of 59.3% compared to S$759,000 for the same period in 2022[31]. Operating Income and Expenses - Other operating income increased to S$572,000 for the three months ended March 31, 2023, compared to S$73,000 for the same period in 2022[11]. - Employee benefits expense was S$797,000 for the three months ended March 31, 2023, compared to S$765,000 for the same period in 2022[11]. - Depreciation of plant and equipment increased to S$68,000 for the three months ended March 31, 2023, from S$33,000 for the same period in 2022[11]. - Other operating expenses rose by approximately S$296,000 or 30.42%, from approximately S$973,000 for the three months ended March 31, 2022, to approximately S$1,269,000 for the same period in 2023[88]. - Consumables and medical supplies used amounted to approximately S$163,000 for the three months ended March 31, 2023, down from S$638,000 in the same period in 2022[68]. Corporate Governance - The Company complied with all applicable code provisions of the Corporate Governance Code during the three months ended March 31, 2023[110]. - The Board is committed to high standards of corporate governance to manage business risks and enhance transparency[109]. - The Company is continuously reviewing and improving its corporate governance practices[109]. - All directors confirmed compliance with the required standard of dealings and the code of conduct regarding securities transactions throughout the three months ended March 31, 2023[122]. - The company has established an Audit Committee in compliance with GEM Listing Rules, consisting of three independent non-executive directors[136]. Share Options and Equity - The company recognized S$344,000 from the exercise of share options during the period[13]. - The total number of share options granted as of March 31, 2023, is 30,000,000, with 18,000,000 exercised and 12,000,000 lapsed[118]. - The Company has a Share Option Scheme that allows for the exercise of options from September 29, 2022, to September 28, 2032, at an exercise price of HK$0.109 per share[115]. - As of March 31, 2023, the total equity was reported at S$7,396,000, a decrease from S$6,288,000 at January 1, 2023[13]. - The weighted average number of ordinary shares in issue increased to 1,231,793,000 for the three months ended March 31, 2023, compared to 930,000,000 in the previous year[48]. Future Strategies - The core business operations will shift to dental implant services, with a two-year business development plan established in 2022[54]. - The Company sees significant market potential for dental implant services in mainland China due to its large population and aging demographic[55]. - Future strategies may include further market expansion and potential new product offerings in the healthcare sector[34]. - The company is focusing on expanding its dental services, which have shown growth potential in the current market[34]. Taxation and Compliance - The company has not reported any current tax expenses for the period, maintaining a tax rate of 17% for Singapore corporate income tax[43]. - Income tax expense remained nil for the three months ended March 31, 2022, and 2023, indicating no taxable income during these periods[90].

Financial Performance - The Group's total assets stripped amounted to S$11,739,000, representing 48.64% of the Group's total assets[18]. - The total revenue of the stripped subsidiaries was approximately S$10,601,000, accounting for 69.03% of the Group's annual total revenue[18]. - The Group's consolidated business revenue as of December 31, 2022, was S$4,241,000[18]. - The consolidated loss for the year attributable to the owners of the Company was approximately S$18,649,000[18]. - Following the divestment, the group's consolidated revenue as of December 31, 2022, was S$4,241,000, with a net loss attributable to the company of approximately S$18,649,000[21]. - Total revenue for the Group was S$4,755,000, while revenue from stripped assets was S$9,656,000, accounting for 67.0% of total revenue[40]. - The total loss attributable to the owners of the Company was S$18,649,000, with losses from stripped assets amounting to S$5,530,000, representing 29.65% of total losses[40]. Business Transformation - Major structural transformations occurred in both management and business during 2022[16]. - The Company faced severe liquidity issues and flaws in its business model, leading to interim judicial management of its three major subsidiaries in Singapore[18]. - The company has shifted its core business operations from dermatological services in Singapore to dental services focused on dental implants in mainland China, with over 40 points of sales contracted as of the end of the reporting period[23]. - The company plans to focus resources on its core dental business in mainland China, leveraging the large population and aging demographics to drive growth[25]. - The strategic transformation is believed to align with the best interests of shareholders and is supported by the feasibility of the new business model[25]. - The divestment of Singapore subsidiaries is expected to have a one-off adverse impact on the group's financial statements but is not anticipated to affect future years[36]. - The company will address historical debt issues and streamline non-core businesses to enhance asset utilization and reduce operating costs[28]. Corporate Governance - An independent internal control auditor was appointed to review the effectiveness of the Company's internal control[17]. - The Company aims to achieve further improvement in corporate governance through the internal control review[17]. - The Company aims to improve corporate governance and management structure to support its business transformation and development plans[24]. - The Company has not reached a consensus on many important issues within the Board as of the end of the reporting period[17]. - The Board experienced significant personnel changes, resulting in material differences in internal management and business direction[17]. Shareholder Information - The Board does not recommend the payment of a final dividend for the year ended December 31, 2022, indicating no distributable reserves available for shareholders[62][80]. - The Group's future cash requirements for development and the economic environment will be considered when determining dividend payouts[68]. - At least 25% of the Company's total issued share capital was held by the public as of the latest practicable date prior to the report[169]. Management and Directors - The executive Directors have service agreements with the Company for an initial term of three years, which can be terminated with three months' notice[93]. - Independent non-executive Directors have letters of appointment for an initial term of two to three years, terminable with at least one month's notice[94]. - The Directors' fees are subject to Shareholders' approval at general meetings, while other emoluments are determined by the Board based on performance and Group results[99]. - The Company has established a Remuneration Committee to review and recommend remuneration policies for Directors and senior management[100]. - There were no significant transactions or contracts involving Directors with material interests during the year ended December 31, 2022[102]. Compliance and Regulations - The Group has complied with all relevant laws and regulations regarding environmental protection, health and safety, and workplace conditions during the year ended December 31, 2022[69]. - The Group does not operate any retirement benefit schemes other than contributions to the Central Provident Fund in Singapore and a Mandatory Provident Fund Scheme in Hong Kong[104]. - The company is licensed to carry out Type 6 regulated activities under the Securities and Futures Ordinance, indicating its compliance with financial regulations[194]. Future Plans - The Company plans to shift its core business operations to dental implant services, aiming to contract at least 530 service outlets and complete no less than 19,000 dental implants by the end of 2023[46]. - The projected sales revenue from dental implants is expected to be no less than RMB97.4 million, with a gross profit of RMB18.7 million[46]. - The rapid expansion of dental service outlets indicates the feasibility of the Company's existing business model in the growing market of mainland China[47]. Auditor and Financial Statements - Shinewing (HK) CPA Limited resigned as the auditor on December 19, 2022, and CL Partners CPA Limited was appointed on December 21, 2022[173]. - The consolidated financial statements for the year ended December 31, 2022, have been audited by CL Partners CPA Limited[173].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對 因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 RMH HOLDINGS LIMITED 德 斯 控 股 有 限 公 司 （於開曼群島註冊成立之有限公司） （股份代號：8437） 截 至2022年12月31日 止 年 度 全 年 業 績 公 告 德斯控股有限公司（「本公司」，連同其附屬公司，統稱「本集團」）董事（「董事」） 會（「董事會」）欣然公告本集團截至2022年12月31日止年度之經審核綜合財 務 業 績。本 公 告 列 載 本 公 司2022年 年 報 全 文（「2022年 年 報」），並 遵 照 聯 交 所GEM證券上市規則（「GEM上市規則」）有關年度業績初步業績公告須包 括 的 資 料 的 相 關 規 定。本 公 司2022年 年 報 的 印 刷 版 本 將 適 時 寄 發 予 本 公 司股東，並將按GEM上市規則所規定的方式於聯交所網站www.hkexnews.hk 及本公司網站www.rmhhk.com可供查閱。 承董事會命 德斯 ...

Financial Performance - The unaudited revenue of RMH Holdings Limited for the nine months ended 30 September 2022 was approximately S$11,436,000, representing an increase of approximately S$3,945,000 or 52.7% compared to S$7,491,000 for the same period in 2021[8][11]. - The unaudited loss for the Group was approximately S$5,887,000 for the nine months ended 30 September 2022, an increase of approximately S$1,716,000 or 41.1% from the loss of S$4,171,000 for the same period in 2021[9][11]. - The total comprehensive loss for the previous period (nine months ended September 30, 2021) was S$4,268,000[16]. - The company reported a loss before taxation of S$5,887,000 for the nine months ended September 30, 2022, compared to a loss of S$4,115,000 in the previous year, reflecting an increase in losses of 43.1%[78]. - The loss per share for the nine months ended 30 September 2022 was S$0.50, compared to S$0.58 for the same period in 2021[10][13]. Revenue Breakdown - Revenue from Aesthetic Services was S$820,000, up 105.3% from S$399,000 in the previous year[72]. - Revenue from Consultation Services increased to S$1,660,000, a rise of 12.9% from S$1,470,000 in 2021[72]. - Prescription and Dispensing Services generated S$2,783,000, compared to S$2,181,000, reflecting a growth of 27.6%[72]. - Treatment Services revenue rose to S$2,398,000, an increase of 13.3% from S$2,116,000 in the prior year[72]. - Trading Sales surged to S$2,420,000, significantly up from S$209,000, marking a growth of 1,055.0%[72]. - Other Services, primarily from laboratory tests, contributed S$1,355,000, an increase from S$1,116,000, representing a growth of 21.4%[72]. Expenses and Costs - Employee benefits expense was approximately S$6,381,000, which increased by approximately S$2,185,000 or 52.1% compared to the previous year, primarily due to additional headcounts at the Hong Kong office[9][11]. - Other operating expenses increased due to derecognition of finance lease receivables and miscellaneous expenses[9][11]. - Total consumables and medical supplies used amounted to approximately S$3,726,000 for the nine months ended 30 September 2022, up from approximately S$1,342,000 in 2021, reflecting increased service demand[116]. - Other operating expenses increased by approximately S$1,427,000 or 35.8% from approximately S$3,986,000 for the nine months ended 30 September 2021 to approximately S$5,413,000 for the nine months ended 30 September 2022[131]. Share Capital and Dividends - The Board did not recommend the payment of any dividend for the nine months ended 30 September 2022[10]. - As of September 30, 2022, the total share capital increased to S$2,240,000 from S$1,483,000 at the beginning of the year[16]. - The company issued shares by placing, raising a total of S$7,469,000 during the period[16]. - The retained earnings as of September 30, 2022, showed a deficit of S$21,970,000, compared to a deficit of S$16,084,000 at the beginning of the year[16]. Corporate Governance - The company has adopted the Corporate Governance Code as its own code of corporate governance[170]. - The company is committed to high standards of corporate governance to manage business risks and enhance transparency[170]. - The company has independent non-executive directors forming the majority of the board, ensuring a balance of power[173]. - The company will continue to review and improve its corporate governance practices[170]. Market Outlook - The Group is cautiously optimistic about a strong rebound in performance for the year 2022, driven by the easing of government anti-COVID-19 measures and the ongoing mass vaccination rollout[105]. - The Group's overall financial position will be closely monitored to evaluate the potential impact of ongoing market conditions[105].

Financial Performance - The unaudited revenue of RMH Holdings Limited for the six months ended June 30, 2022, was approximately S$7,713,000, representing an increase of approximately S$3,090,000 or 66.8% compared to S$4,623,000 for the same period in 2021[9]. - The unaudited loss for the Group was approximately S$4,948,000 for the six months ended June 30, 2022, an increase of approximately S$2,119,000 or 74.9% compared to a loss of S$2,829,000 for the same period in 2021[10]. - The total comprehensive loss for the period was S$5,048,000, compared to S$2,885,000 for the same period in 2021[14]. - The company reported a loss before taxation of S$4,948,000 for the six months ended June 30, 2022, compared to a loss of S$2,791,000 in the same period of 2021[24]. - Total comprehensive loss for the period was S$5,046,000, compared to S$4,947,000 in the previous year[21]. - Loss attributable to the owners of the Company for the six months ended 30 June 2022 was S$4,948,000, compared to S$2,829,000 for the same period in 2021, representing an increase of 74.8%[109]. - Loss per share was 0.44 Singapore cents for the six months ended June 30, 2022, compared to 0.40 Singapore cents for the same period in 2021[11]. Revenue Breakdown - Revenue from healthcare services amounted to S$5,481,000, up 17.6% from S$4,661,000 in 2021[91]. - Trading sales significantly increased to S$1,946,000 from S$157,000, marking a substantial growth[91]. - Revenue recognized at a point in time was S$4,602,000, compared to S$2,179,000, reflecting a 111.0% increase[87]. - Other services, primarily related to laboratory tests, generated S$862,000, an increase of 20.1% from S$718,000[87]. - The Group's healthcare services revenue breakdown includes S$506,000 from Aesthetic Services, S$1,116,000 from Consultation Services, S$1,793,000 from Prescription and Dispensing Services, and S$1,489,000 from Treatment Services[186]. - Revenue from Aesthetic Services was S$506,000 for the six months ended 30 June 2022, attributed to increased capacity following the easing of COVID-19 measures and new dermatologists joining[188]. - Consultation Services revenue increased by approximately S$170,000, from S$946,000 in the six months ended June 30, 2021 to approximately S$1,116,000 in the same period of 2022[188]. - Revenue from Prescription and Dispensing Services rose by approximately S$387,000, from S$1,406,000 for the six months ended June 30, 2021 to approximately S$1,793,000 for the same period in 2022[188]. - Treatment Services revenue increased by approximately S$222,000, from S$1,267,000 in the six months ended June 30, 2021 to approximately S$1,489,000 in the same period of 2022, driven by excision, MOHS light, and cryosurgery[188]. - Other Services revenue increased by approximately S$144,000, from S$718,000 for the six months ended June 30, 2021 to approximately S$862,000 for the same period in 2022[188]. Operational Costs and Expenses - Employee benefits expense amounted to approximately S$4,274,000, reflecting an increase of approximately S$1,585,000 or 58.9% due to additional headcounts[10]. - The company incurred professional and consulting fees of S$2,100,000, an increase from S$1,623,000 in the prior year[102]. - Total consumables and medical supplies used amounted to approximately S$2,597,000 for the six months ended June 30, 2022, up from S$722,000 in 2021, reflecting increased revenue from Prescription and Dispensing Services[191]. - Depreciation and amortization expenses totaled S$1,935,000, reflecting ongoing investments in plant and equipment and intangible assets[24]. - The total compensation for key management personnel during the period was S$1,235,000, up from S$787,000 in the previous year, representing a 57% increase[170]. Assets and Liabilities - As of June 30, 2022, total assets amounted to S$17,619,000, an increase from S$9,634,000 as of December 31, 2021[17]. - Net current assets increased to S$4,257,000 from S$2,777,000, reflecting improved liquidity[17]. - The company’s net assets increased to S$6,713,000 from S$4,567,000, indicating a stronger equity position[17]. - Trade receivables as of 30 June 2022 amounted to S$3,096,000, with a loss allowance of S$995,000, compared to S$2,230,000 and S$779,000 respectively in 2021, indicating an increase in both receivables and allowances[122]. - Total deposits increased to S$6,074,000 as of 30 June 2022, compared to S$1,958,000 in the previous year, reflecting a significant increase of 210%[122]. - The Group's total trade and other receivables amounted to S$12,587,000 as of 30 June 2022, compared to S$5,766,000 in 2021, indicating a substantial increase of 118%[122]. - Trade payables increased significantly to S$8,498,000 as of June 30, 2022, compared to S$3,259,000 as of December 31, 2021[154]. - The total amount of trade receivables that are not past due is S$634,000, while those overdue between 91 to 120 days amount to S$124,000[134]. Cash Flow and Financing - Operating cash flows before working capital changes were negative at S$1,639,000, indicating challenges in cash generation[24]. - Cash used in operating activities was S$3,706,000, up from S$1,996,000 in the previous year, highlighting increased operational cash outflows[24]. - Cash used in investing activities amounted to S$2,406,000, a significant increase from S$783,000 in the previous period[27]. - Cash from financing activities totaled S$5,210,000, up from S$2,861,000 in the previous period[27]. - The cash and cash equivalents at the end of the period were S$1,030,000, a decrease from S$4,871,000 at the end of the previous period[27]. - The company reported a repayment of borrowings totaling S$726,000, compared to S$181,000 in the prior period[27]. - The company has a loan of S$3 million with a repayment period of 60 months, which commenced on June 22, 2020, secured by a corporate guarantee[162]. - The total borrowings as of June 30, 2022, amounted to S$6,112,000, slightly up from S$6,067,000 as of December 31, 2021, indicating a marginal increase of 0.74%[158]. Credit Risk and Impairment - The Group recognizes expected credit losses (ECL) on financial assets subject to impairment under IFRS 9, including trade and other receivables, finance lease receivables, and cash equivalents[39]. - The Group always recognizes lifetime ECL for trade receivables and lease receivables, estimating losses using a provision matrix based on historical credit loss experience[39]. - The expected credit loss rate for trade receivables is less than 1%, indicating a low risk of default among customers[135]. - The ageing analysis of trade receivables shows that S$1,284,000 is overdue by more than 90 days, contributing to a total of S$2,101,000 in trade receivables[137]. - Credit-impaired financial assets are identified when events negatively impact the estimated future cash flows, such as significant financial difficulty of the borrower or breach of contract[53]. Strategic Developments - The Group has established a Mohs Micrographic Surgery Centre and a Mole Mapping Centre at Orchard Clinic, employing 3 Mohs Dermato-Surgeons, and opened a new dermatology clinic at Gleneagles Medical Centre in Singapore[183]. - The Group anticipates continued revenue improvement from clinics in Singapore and Hong Kong due to easing government anti-COVID-19 measures and mass vaccination rollouts[183]. - The Group has decided to suspend business development for its wholly-owned subsidiary, RMH Imaging Limited, due to significant market changes and differing future prospects[183]. - The management believes that the significant impairment in the investment portfolio will not have a continuous impact on the principal businesses and long-term operations of the Group[176]. - The Group is cautiously optimistic about rebounding strongly to profitability in 2022 due to a reasonably healthy cash reserve and intact business operations[182].

Financial Performance - The unaudited revenue of RMH Holdings Limited for the three months ended March 31, 2022, was approximately S$3,311,000, representing an increase of approximately S$1,151,000 or 53.3% compared to S$2,160,000 for the same period in 2021[7][11]. - The unaudited loss for the Group was approximately S$2,529,000 for the three months ended March 31, 2022, which is an increase of approximately S$1,621,000 or 178.5% compared to a loss of S$908,000 for the same period in 2021[8][11]. - Loss per share for the Company was approximately 0.27 Singapore cents for the three months ended March 31, 2022, compared to approximately 0.13 Singapore cents for the same period in 2021[9][11]. - The total comprehensive loss for the period was S$2,529,000, reflecting the overall financial performance of the Group[13]. - The Group's other operating income for the three months ended March 31, 2022, was S$223,000, compared to S$295,000 for the same period in 2021[13]. - The total comprehensive loss includes a foreign currency translation income of S$22,000 for the period[13]. - The Group's total equity as of March 31, 2022, was S$9,253,000, reflecting the financial position of the Company[15]. - The increase in losses was attributed to higher operating expenses and costs associated with the Group's activities during the period[8][11]. Revenue Breakdown - Revenue for the three months ended March 31, 2022, was S$3,311,000, representing a 53% increase from S$2,160,000 in the same period of 2021[36]. - Aesthetic services revenue increased to S$149,000 from S$88,000, a growth of 69% year-over-year[36]. - Consultation services revenue rose to S$541,000, up 21% from S$448,000 in the previous year[36]. - Trading sales surged to S$760,000 compared to S$31,000 in the same period last year, indicating a significant increase[36]. - Revenue recognized at a point in time was S$1,990,000, up from S$1,033,000, reflecting a 92% increase[36]. - Revenue recognized over time was S$1,321,000, compared to S$1,127,000, marking a 17% increase[36]. - Revenue from Singapore was S$2,551,000, up from S$2,160,000 in 2021, while revenue from Hong Kong was S$760,000, which was not reported in the previous year[42]. - Revenue from Aesthetic Services rose by approximately S$61,000 from S$88,000 for the three months ended March 31, 2021 to S$149,000 for the three months ended March 31, 2022[73]. - Revenue from Consultation Services increased by approximately S$93,000 from S$448,000 for the three months ended March 31, 2021 to S$541,000 for the three months ended March 31, 2022, with patient visits rising by 22.1%[75]. - Revenue from Prescription and Dispensing Services increased by approximately S$211,000 from S$675,000 in Q1 2021 to S$886,000 in Q1 2022, reflecting an increase in patient visits[77]. - Revenue from Treatment Services rose by approximately S$39,000 from S$591,000 in Q1 2021 to S$630,000 in Q1 2022, driven by excision, skin check, kenacort, and cryosurgery[77]. - Revenue from Other Services increased by approximately S$18,000 from S$327,000 in Q1 2021 to S$345,000 in Q1 2022, primarily from laboratory tests and medical examinations[77]. - Trading Sales contributed approximately S$760,000 in Q1 2022, an increase of approximately S$729,000 compared to S$31,000 in Q1 2021[77]. Operating Expenses - The company reported a loss before tax, with significant expenses including professional and consulting fees amounting to S$1,122,000, compared to S$717,000 in 2021[53]. - Employee benefits expense rose to S$1,951,000 in Q1 2022 from S$1,175,000 in Q1 2021, largely due to additional dermatologists[83]. - Other operating expenses increased by approximately S$1,008,000 or 119% from S$847,000 in Q1 2021 to S$1,855,000 in Q1 2022[93]. - Other operating income decreased by S$72,000 from approximately S$295,000 in Q1 2021 to approximately S$223,000 in Q1 2022[80]. - Consumables and medical supplies used increased to approximately S$1,138,000 in Q1 2022 from S$330,000 in Q1 2021, in line with revenue growth[80]. - Other expenses increased due to nonrecurring marketing and advertising expenses aimed at creating market awareness for the new aesthetic clinic[99]. Corporate Governance - The company adopted the Corporate Governance Code and complied with all applicable provisions during the three months ended March 31, 2022[120]. - The board is committed to high standards of corporate governance to manage business risks and enhance transparency[119]. - The Audit Committee consists of three independent non-executive Directors, ensuring compliance with GEM Listing Rules[128]. - The Audit Committee reviewed the Group's unaudited condensed consolidated financial statements for the three months ended March 31, 2022[129]. - All directors confirmed compliance with the required standard of dealings regarding securities transactions during the reporting period[123]. - The board will continue to review and improve the company's corporate governance practices[119]. Shareholder Information - The company had a significant shareholder, Dr. Loh Teck Hiong, holding 210,024,000 shares, representing 16.21% of the company[104]. - As of March 31, 2022, Brisk Success holds 210,024,000 shares, representing a 16.21% interest in the company[115]. - HK MZ Health Investment holds 132,968,000 shares, accounting for 10.26% of the company's interest[115]. - No share options were granted by the company from September 22, 2017, to the date of the report[123]. - The company and its subsidiaries did not purchase, sell, or redeem any shares during the three months ended March 31, 2022[123]. - No rights to acquire shares or debentures were granted to directors or their family members during the reporting period[123]. - The company has not disclosed any interests or short positions in shares that require disclosure under the SFO as of March 31, 2022[118]. Future Outlook - The company continues to focus on strategic initiatives to enhance its market position and operational efficiency moving forward[11]. - The Group expects continued improvement in revenue at a faster rate from clinics in both Singapore and Hong Kong due to easing COVID-19 measures[65]. - The Company is cautiously optimistic about returning to profitability in the second quarter of 2022[65]. - The sales of Regenerative Medicine products remained lackluster due to the continued closure of the Hong Kong-China border[65].